Inqovi (Decitabine/Cedazuridine) Patent Expiration, LOE Window & CMS Spending

Inqovi (Decitabine/Cedazuridine) by Taiho Oncology: FDA Orange Book core substance LOE 2034-02-12 (last listed 2042-12-10), 0 AB generics, $96.4M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTaiho Oncology
FDA Application & PathwayN212576 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2034-02-12
Last Listed Patent or Exclusivity Date2042-12-10
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$96.4M
2024 Medicare Part D Spend$94.5M
2024 Medicaid Spend$1.9M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel